Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
CpTM complexes for imaging of ER-positive tumors evaluated
May 19th, 2005
Novel CpTM complexes have been developed for imaging breast tumors expressing estrogen receptor (ER). In a study from the United States, "[c]yclopentadienyl tricarbonylmetal (CpTM, M=Re, 94mTc) complexes, some based on a typical nonsteroidal estrogen, were prepared with the aim of developing technetium- and rhenium-labeled imaging agents" for ER-positive breast tumors. "CpT[94mTc] compounds with simple cyclopentadienyl substituents were first synthesized using a modified double ligand transfer reaction," explained H.M. Bigott and coauthors at Washington University. "The in vivo biodistribution of one of these...
Source: Women's Health Weekly (2005-05-19)
|
